Digging a hole under Hedgehog: Downstream inhibition as an emerging anticancer strategy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1856, Issue 1, 2015, Pages 62-72

  Di Magno, Laura ^b   Coni, Sonia ^a   Di Marcotullio, Lucia ^a   Canettieri, Gianluca ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Cancer therapy; Epigenetics; Gli; Hedgehog; Metabolism; Smo

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 6 ETHYL 4,5 DIHYDRO N [1 (HYDROXYACETYL) 4 PIPERIDINYL] 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) 3 (2,2,2 TRIFLUOROETHOXY) 1H PYRROLO[3,2 C]PYRIDINE 2 CARBOXAMIDE; ARSENIC TRIOXIDE; BMS 833923; CYCLOPAMINE; DICHLOROACETIC ACID; EVEROLIMUS; FATTY ACID SYNTHASE; GLASDEGIB; HISTONE DEACETYLASE INHIBITOR; IMIQUIMOD; ITRACONAZOLE; PATIDEGIB; PROTEIN PATCHED; PYRUVATE DEHYDROGENASE KINASE; PYRVINIUM EMBONATE; RICOLINOSTAT; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; SONIDEGIB; SUNITINIB; TALADEGIB; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR GLI3; VISMODEGIB; VORINOSTAT; ZERUMBONE; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; AUTOCRINE EFFECT; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BILE DUCT CARCINOMA; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; COLON CANCER; COLORECTAL CANCER; DRUG POTENTIATION; EWING SARCOMA; GERMLINE MUTATION; GLIOBLASTOMA; GLYCOLYSIS; HISTONE ACETYLATION; HUMAN; LACTIC ACIDOSIS; LIPOGENESIS; LOSS OF FUNCTION MUTATION; MEDULLOBLASTOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PARACRINE SIGNALING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; SOLID TUMOR; SOMATIC MUTATION; STOMACH CANCER; TUMOR REGRESSION; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION;

ERINACEIDAE;

ANTINEOPLASTIC AGENTS; HEDGEHOG PROTEINS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84934937938     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.06.003     Document Type: Review

References (137)

1. Brechbiel J., Miller-Moslin K., Adjei A.A. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat. Rev. 2014, 40:750-759.
2. Merchant A.A., Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin. Cancer Res. 2010, 16:3130-3140.
3. Chuang P.T., McMahon A.P. Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. Nature 1999, 397:617-621.
4. Allen B.L., Tenzen T., McMahon A.P. The Hedgehog-binding proteins Gas1 and Cdo cooperate to positively regulate Shh signaling during mouse development. Genes Dev. 2007, 21:1244-1257.
5. van den Heuvel M., Ingham P.W. Smoothened encodes a receptor-like serpentine protein required for hedgehog signalling. Nature 1996, 382:547-551.
6. Rohatgi R., Milenkovic L., Scott M.P. Patched1 regulates hedgehog signaling at the primary cilium. Science 2007, 317:372-376.
7. Rohatgi R., Milenkovic L., Corcoran R.B., Scott M.P. Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3196-3201.
8. Svard J., Heby-Henricson K., Persson-Lek M., Rozell B., Lauth M., Bergstrom A., Ericson J., Toftgard R., Teglund S. Genetic elimination of suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev. Cell 2006, 10:187-197.
9. Kogerman P., Grimm T., Kogerman L., Krause D., Unden A.B., Sandstedt B., Toftgard R., Zaphiropoulos P.G. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat. Cell Biol. 1999, 1:312-319.
10. Humke E.W., Dorn K.V., Milenkovic L., Scott M.P., Rohatgi R. The output of Hedgehog signaling is controlled by the dynamic association between suppressor of fused and the Gli proteins. Genes Dev. 2010, 24:670-682.
11. Lee Y., Kawagoe R., Sasai K., Li Y., Russell H.R., Curran T., McKinnon P.J. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 2007, 26:6442-6447.
12. Jiang J., Hui C.C. Hedgehog signaling in development and cancer. Dev. Cell 2008, 15:801-812.
13. Ruiz i Altaba A., Mas C., Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 2007, 17:438-447.
14. Canettieri G., Di Marcotullio L., Greco A., Coni S., Antonucci L., Infante P., Pietrosanti L., De Smaele E., Ferretti E., Miele E., Pelloni M., De Simone G., Pedone E.M., Gallinari P., Giorgi A., Steinkuhler C., Vitagliano L., Pedone C., Schinin M.E., Screpanti I., Gulino A. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat. Cell Biol. 2010, 12:132-142.
15. Wang Y., Ding Q., Yen C.J., Xia W., Izzo J.G., Lang J.Y., Li C.W., Hsu J.L., Miller S.A., Wang X., Lee D.F., Hsu J.M., Huo L., Labaff A.M., Liu D., Huang T.H., Lai C.C., Tsai F.J., Chang W.C., Chen C.H., Wu T.T., Buttar N.S., Wang K.K., Wu Y., Wang H., Ajani J., Hung M.C. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012, 21:374-387.
16. Robbins D.J., Fei D.L., Riobo N.A. The Hedgehog signal transduction network. Sci. Signal. 2012, 5:re6.
17. Stecca B., Ruiz I.A.A. Context-dependent regulation of the GLI code in cancer by Hedgehog and non-Hedgehog signals. J. Mol. Cell Biol. 2010, 2:84-95.
18. Teperino R., Amann S., Bayer M., McGee S.L., Loipetzberger A., Connor T., Jaeger C., Kammerer B., Winter L., Wiche G., Dalgaard K., Selvaraj M., Gaster M., Lee-Young R.S., Febbraio M.A., Knauf C., Cani P.D., Aberger F., Penninger J.M., Pospisilik J.A., Esterbauer H. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell 2012, 151:414-426.
19. Po A., Ferretti E., Miele E., De Smaele E., Paganelli A., Canettieri G., Coni S., Di Marcotullio L., Biffoni M., Massimi L., Di Rocco C., Screpanti I., Gulino A. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J. 2010, 29:2646-2658.
20. Oliver T.G., Grasfeder L.L., Carroll A.L., Kaiser C., Gillingham C.L., Lin S.M., Wickramasinghe R., Scott M.P., Wechsler-Reya R.J. Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7331-7336.
21. O'Brien C.A., Kreso A., Jamieson C.H. Cancer stem cells and self-renewal. Clin. Cancer Res. 2010, 16:3113-3120.
22. Scales S.J., de Sauvage F.J. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol. Sci. 2009, 30:303-312.
23. Epstein E.H. Basal cell carcinomas: attack of the hedgehog. Nat. Rev. Cancer 2008, 8:743-754.
24. Diepgen T.L., Mahler V. The epidemiology of skin cancer. Br. J. Dermatol. 2002, 146(Suppl. 61):1-6.
25. Nilsson M., Unden A.B., Krause D., Malmqwist U., Raza K., Zaphiropoulos P.G., Toftgard R. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3438-3443.
26. Grachtchouk M., Mo R., Yu S., Zhang X., Sasaki H., Hui C.C., Dlugosz A.A. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat. Genet. 2000, 24:216-217.
27. Crawford J.R., MacDonald T.J., Packer R.J. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007, 6:1073-1085.
28. Rusert J.M., Wu X., Eberhart C.G., Taylor M.D., Wechsler-Reya R.J. SnapShot: Medulloblastoma. Cancer Cell 2014, 26:940. (e941).
29. Lin T.L., Matsui W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. OncoTargets Ther. 2012, 5:47-58.
30. Karhadkar S.S., Bova G.S., Abdallah N., Dhara S., Gardner D., Maitra A., Isaacs J.T., Berman D.M., Beachy P.A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431:707-712.
31. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
32. Watkins D.N., Berman D.M., Baylin S.B. Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Cell Cycle 2003, 2:196-198.
33. Dyer M.A., Farrington S.M., Mohn D., Munday J.R., Baron M.H. Indian hedgehog activates hematopoiesis and vasculogenesis and can respecify prospective neurectodermal cell fate in the mouse embryo. Development 2001, 128:1717-1730.
34. Stecca B., Mas C., Clement V., Zbinden M., Correa R., Piguet V., Beermann F., Ruiz I.A.A. Melanomas require Hedgehog-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:5895-5900.
35. Sicklick J.K., Li Y.X., Jayaraman A., Kannangai R., Qi Y., Vivekanandan P., Ludlow J.W., Owzar K., Chen W., Torbenson M.S., Diehl A.M. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006, 27:748-757.
36. Cutcliffe C., Kersey D., Huang C.C., Zeng Y., Walterhouse D., Perlman E.J., G.Renal Tumor Committee of the Children's Oncology Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin. Cancer Res. 2005, 11:7986-7994.
37. Bhattacharya R., Kwon J., Ali B., Wang E., Patra S., Shridhar V., Mukherjee P. Role of hedgehog signaling in ovarian cancer. Clin. Cancer Res. 2008, 14:7659-7666.
38. Berman D.M., Karhadkar S.S., Maitra A., Montes De Oca R., Gerstenblith M.R., Briggs K., Parker A.R., Shimada Y., Eshleman J.R., Watkins D.N., Beachy P.A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425:846-851.
39. Ho L., Stojanovski A., Whetstone H., Wei Q.X., Mau E., Wunder J.S., Alman B. Gli2 and p53 cooperate to regulate IGFBP-3-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 2009, 16:126-136.
40. Kinzler K.W., Bigner S.H., Bigner D.D., Trent J.M., Law M.L., O'Brien S.J., Wong A.J., Vogelstein B. Identification of an amplified, highly expressed gene in a human glioma. Science 1987, 236:70-73.
41. Kinzler K.W., Ruppert J.M., Bigner S.H., Vogelstein B. The GLI gene is a member of the Kruppel family of zinc finger proteins. Nature 1988, 332:371-374.
42. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
43. Taipale J., Chen J.K., Cooper M.K., Wang B., Mann R.K., Milenkovic L., Scott M.P., Beachy P.A. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000, 406:1005-1009.
44. Cooper M.K., Porter J.A., Young K.E., Beachy P.A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 1998, 280:1603-1607.
45. Chen J.K., Taipale J., Cooper M.K., Beachy P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002, 16:2743-2748.
46. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernandez-del Castillo C., Yajnik V., Antoniu B., McMahon M., Warshaw A.L., Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
47. Berman D.M., Karhadkar S.S., Hallahan A.R., Pritchard J.I., Eberhart C.G., Watkins D.N., Chen J.K., Cooper M.K., Taipale J., Olson J.M., Beachy P.A. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002, 297:1559-1561.
48. Sanchez P., Ruiz i Altaba A. In vivo inhibition of endogenous brain tumors through systemic interference of Hedgehog signaling in mice. Mech. Dev. 2005, 122:223-230.
49. Watkins D.N., Berman D.M., Burkholder S.G., Wang B., Beachy P.A., Baylin S.B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422:313-317.
50. De Smaele E., Ferretti E., Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr. Opin. Investig. Drugs 2010, 11:707-718.
51. Jimeno A., Weiss G.J., Miller W.H., Gettinger S., Eigl B.J., Chang A.L., Dunbar J., Devens S., Faia K., Skliris G., Kutok J., Lewis K.D., Tibes R., Sharfman W.H., Ross R.W., Rudin C.M. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin. Cancer Res. 2013, 19:2766-2774.
52. Lee M.J., Hatton B.A., Villavicencio E.H., Khanna P.C., Friedman S.D., Ditzler S., Pullar B., Robison K., White K.F., Tunkey C., LeBlanc M., Randolph-Habecker J., Knoblaugh S.E., Hansen S., Richards A., Wainwright B.J., McGovern K., Olson J.M. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7859-7864.
53. Buonamici S., Williams J., Morrissey M., Wang A., Guo R., Vattay A., Hsiao K., Yuan J., Green J., Ospina B., Yu Q., Ostrom L., Fordjour P., Anderson D.L., Monahan J.E., Kelleher J.F., Peukert S., Pan S., Wu X., Maira S.M., Garcia-Echeverria C., Briggs K.J., Watkins D.N., Yao Y.M., Lengauer C., Warmuth M., Sellers W.R., Dorsch M. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2010, 2:51ra70.
54. Nanta R., Kumar D., Meeker D., Rodova M., Van Veldhuizen P.J., Shankar S., Srivastava R.K. NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rgamma null mice by regulating Bmi-1 and microRNA-128. Oncogenesis 2013, 2:e42.
55. D'Amato C., Rosa R., Marciano R., D'Amato V., Formisano L., Nappi L., Raimondo L., Di Mauro C., Servetto A., Fulciniti F., Cipolletta A., Bianco C., Ciardiello F., Veneziani B.M., De Placido S., Bianco R. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br. J. Cancer 2014, 111:1168-1179.
56. Justilien V., Fields A.P. Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin. Cancer Res. 2015, 21:505-513.
57. Kim J., Tang J.Y., Gong R., Kim J., Lee J.J., Clemons K.V., Chong C.R., Chang K.S., Fereshteh M., Gardner D., Reya T., Liu J.O., Epstein E.H., Stevens D.A., Beachy P.A. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010, 17:388-399.
58. Kim J., Aftab B.T., Tang J.Y., Kim D., Lee A.H., Rezaee M., Kim J., Chen B., King E.M., Borodovsky A., Riggins G.J., Epstein E.H., Beachy P.A., Rudin C.M. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013, 23:23-34.
59. Kim D.J., Kim J., Spaunhurst K., Montoya J., Khodosh R., Chandra K., Fu T., Gilliam A., Molgo M., Beachy P.A., Tang J.Y. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J. Clin. Oncol. 2014, 32:745-751.
60. Omenetti A., Diehl A.M. Hedgehog signaling in cholangiocytes. Curr. Opin. Gastroenterol. 2011, 27:268-275.
61. Fingas C.D., Bronk S.F., Werneburg N.W., Mott J.L., Guicciardi M.E., Cazanave S.C., Mertens J.C., Sirica A.E., Gores G.J. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011, 54:2076-2088.
62. Riedlinger D., Bahra M., Boas-Knoop S., Lippert S., Bradtmoller M., Guse K., Seehofer D., Bova R., Sauer I.M., Neuhaus P., Koch A., Kamphues C. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 2014, 21:607-615.
63. Williams J.A., Guicherit O.M., Zaharian B.I., Xu Y., Chai L., Wichterle H., Kon C., Gatchalian C., Porter J.A., Rubin L.L., Wang F.Y. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4616-4621.
64. Tang T., Tang J.Y., Li D., Reich M., Callahan C.A., Fu L., Yauch R.L., Wang F., Kotkow K., Chang K.S., Shpall E., Wu A., Rubin L.L., Marsters J.C., Epstein E.H., Caro I., de Sauvage F.J. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin. Cancer Res. 2011, 17:3378-3387.
65. Wagner A.J., Messersmith W.A., Shaik M.N., Li S., Zheng X., McLachlan K.R., Cesari R., Courtney R., Levin W.J., El-Khoueiry A.B. A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 2015, 21:1044-1051.
66. Ibuki N., Ghaffari M., Pandey M., Iu I., Fazli L., Kashiwagi M., Tojo H., Nakanishi O., Gleave M.E., Cox M.E. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int. J. Cancer 2013, 133:1955-1966.
67. Peukert S., He F., Dai M., Zhang R., Sun Y., Miller-Moslin K., McEwan M., Lagu B., Wang K., Yusuff N., Bourret A., Ramamurthy A., Maniara W., Amaral A., Vattay A., Wang A., Guo R., Yuan J., Green J., Williams J., Buonamici S., Kelleher J.F., Dorsch M. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem 2013, 8:1261-1265.
68. Molckovsky A., Siu L.L. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol. 2008, 1:20.
69. Von Hoff D.D., LoRusso P.M., Rudin C.M., Reddy J.C., Yauch R.L., Tibes R., Weiss G.J., Borad M.J., Hann C.L., Brahmer J.R., Mackey H.M., Lum B.L., Darbonne W.C., Marsters J.C., de Sauvage F.J., Low J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 2009, 361:1164-1172.
70. Sekulic A., Migden M.R., Oro A.E., Dirix L., Lewis K.D., Hainsworth J.D., Solomon J.A., Yoo S., Arron S.T., Friedlander P.A., Marmur E., Rudin C.M., Chang A.L., Low J.A., Mackey H.M., Yauch R.L., Graham R.A., Reddy J.C., Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 2012, 366:2171-2179.
71. Rudin C.M., Hann C.L., Laterra J., Yauch R.L., Callahan C.A., Fu L., Holcomb T., Stinson J., Gould S.E., Coleman B., LoRusso P.M., Von Hoff D.D., de Sauvage F.J., Low J.A. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 2009, 361:1173-1178.
72. Asklund T., Henriksson R., Axelsson J., Bergstrom A., Kasper M., Ogren M., Toftgard R., Riklund K.A. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma. Acta Oncol. 2013, 52:862-866.
73. Atwood S.X., Chang A.L., Oro A.E. Hedgehog pathway inhibition and the race against tumor evolution. J. Cell Biol. 2012, 199:193-197.
74. Yauch R.L., Dijkgraaf G.J., Alicke B., Januario T., Ahn C.P., Holcomb T., Pujara K., Stinson J., Callahan C.A., Tang T., Bazan J.F., Kan Z., Seshagiri S., Hann C.L., Gould S.E., Low J.A., Rudin C.M., de Sauvage F.J. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009, 326:572-574.
75. Sharpe H.J., Pau G., Dijkgraaf G.J., Basset-Seguin N., Modrusan Z., Januario T., Tsui V., Durham A.B., Dlugosz A.A., Haverty P.M., Bourgon R., Tang J.Y., Sarin K.Y., Dirix L., Fisher D.C., Rudin C.M., Sofen H., Migden M.R., Yauch R.L., de Sauvage F.J. Genomic analysis of smoothened inhibitor resistance in Basal cell carcinoma. Cancer Cell 2015, 27:327-341.
76. Atwood S.X., Sarin K.Y., Whitson R.J., Li J.R., Kim G., Rezaee M., Ally M.S., Kim J., Yao C., Chang A.L., Oro A.E., Tang J.Y. Smoothened variants explain the majority of drug resistance in Basal cell carcinoma. Cancer Cell 2015, 27:342-353.
77. Dijkgraaf G.J., Alicke B., Weinmann L., Januario T., West K., Modrusan Z., Burdick D., Goldsmith R., Robarge K., Sutherlin D., Scales S.J., Gould S.E., Yauch R.L., de Sauvage F.J. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011, 71:435-444.
78. Rajurkar M., De Jesus-Monge W.E., Driscoll D.R., Appleman V.A., Huang H., Cotton J.L., Klimstra D.S., Zhu L.J., Simin K., Xu L., McMahon A.P., Lewis B.C., Mao J. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1038-E1047.
79. Zwerner J.P., Joo J., Warner K.L., Christensen L., Hu-Lieskovan S., Triche T.J., May W.A. The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene 2008, 27:3282-3291.
80. Beauchamp E., Bulut G., Abaan O., Chen K., Merchant A., Matsui W., Endo Y., Rubin J.S., Toretsky J., Uren A. GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein. J. Biol. Chem. 2009, 284:9074-9082.
81. Atwood S.X., Li M., Lee A., Tang J.Y., Oro A.E. GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature 2013, 494:484-488.
82. Lauth M., Bergstrom A., Shimokawa T., Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8455-8460.
83. Joo J., Christensen L., Warner K., States L., Kang H.G., Vo K., Lawlor E.R., May W.A. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors. PLoS One 2009, 4:e7608.
84. Mechlin C.W., Tanner M.J., Chen M., Buttyan R., Levin R.M., Mian B.M. Gli2 expression and human bladder transitional carcinoma cell invasiveness. J. Urol. 2010, 184:344-351.
85. Desch P., Asslaber D., Kern D., Schnidar H., Mangelberger D., Alinger B., Stoecher M., Hofbauer S.W., Neureiter D., Tinhofer I., Aberger F., Hartmann T.N., Greil R. Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene 2010, 29:4885-4895.
86. Mazumdar T., DeVecchio J., Shi T., Jones J., Agyeman A., Houghton J.A. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res. 2011, 71:1092-1102.
87. Mazumdar T., Devecchio J., Agyeman A., Shi T., Houghton J.A. Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res. 2011, 71:5904-5914.
88. Yan M., Wang L., Zuo H., Zhang Z., Chen W., Mao L., Zhang P. HH/GLI signalling as a new therapeutic target for patients with oral squamous cell carcinoma. Oral Oncol. 2011, 47:504-509.
89. Shi I., Hashemi Sadraei N., Duan Z.H., Shi T. Aberrant signaling pathways in squamous cell lung carcinoma. Cancer Informat. 2011, 10:273-285.
90. Huang L., Walter V., Hayes D.N., Onaitis M. Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. Clin. Cancer Res. 2014, 20:1566-1575.
91. Pan D., Li Y., Li Z., Wang Y., Wang P., Liang Y. Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leuk. Res. 2012, 36:742-748.
92. Wellbrock J., Latuske E., Kohler J., Wagner K., Stamm H., Vettorazzi E., Vohwinkel G., Klokow M., Kuhling-Thees R., Ehm P., Riecken K., Loges S., Thol F., Schubert C., Amling M., Jucker M., Bokemeyer C., Heuser M., Krauter J., Fiedler W. Expression of Hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts anti-leukemic effects. Clin. Cancer Res. 2015, 21:2388-2398.
93. Wickstrom M., Dyberg C., Shimokawa T., Milosevic J., Baryawno N., Fuskevag O.M., Larsson R., Kogner P., Zaphiropoulos P.G., Johnsen J.I. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int. J. Cancer 2013, 132:1516-1524.
94. Chen Q., Xu R., Zeng C., Lu Q., Huang D., Shi C., Zhang W., Deng L., Yan R., Rao H., Gao G., Luo S. Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin beta4-mediated FAK signaling. PLoS One 2014, 9:e88386.
95. Shahi M.H., Holt R., Rebhun R.B. Blocking signaling at the level of GLI regulates downstream gene expression and inhibits proliferation of canine osteosarcoma cells. PLoS One 2014, 9:e96593.
96. Nagao-Kitamoto H., Nagata M., Nagano S., Kitamoto S., Ishidou Y., Yamamoto T., Nakamura S., Tsuru A., Abematsu M., Fujimoto Y., Yokouchi M., Kitajima S., Yoshioka T., Maeda S., Yonezawa S., Komiya S., Setoguchi T. GLI2 is a novel therapeutic target for metastasis of osteosarcoma. Int. J. Cancer 2015, 136:1276-1284.
97. Wang Y., Han C., Lu L., Magliato S., Wu T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology 2013, 58:995-1010.
98. Srivastava R.K., Kaylani S.Z., Edrees N., Li C., Talwelkar S.S., Xu J., Palle K., Pressey J.G., Athar M. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis. Oncotarget 2014, 5:12151-12165.
99. Hyman J.M., Firestone A.J., Heine V.M., Zhao Y., Ocasio C.A., Han K., Sun M., Rack P.G., Sinha S., Wu J.J., Solow-Cordero D.E., Jiang J., Rowitch D.H., Chen J.K. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14132-14137.
100. Xu Y., Chenna V., Hu C., Sun H.X., Khan M., Bai H., Yang X.R., Zhu Q.F., Sun Y.F., Maitra A., Fan J., Anders R.A. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 2012, 18:1291-1302.
101. Chenna V., Hu C., Pramanik D., Aftab B.T., Karikari C., Campbell N.R., Hong S.M., Zhao M., Rudek M.A., Khan S.R., Rudin C.M., Maitra A. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol. Cancer Ther. 2012, 11:165-173.
102. Kim J., Lee J.J., Kim J., Gardner D., Beachy P.A. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13432-13437.
103. Beauchamp E.M., Ringer L., Bulut G., Sajwan K.P., Hall M.D., Lee Y.C., Peaceman D., Ozdemirli M., Rodriguez O., Macdonald T.J., Albanese C., Toretsky J.A., Uren A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J. Clin. Invest. 2011, 121:148-160.
104. Infante P., Mori M., Alfonsi R., Ghirga F., Aiello F., Toscano S., Ingallina C., Siler M., Cucchi D., Po A., Miele E., D'Amico D., Canettieri G., De Smaele E., Ferretti E., Screpanti I., Uccello Barretta G., Botta M., Botta B., Gulino A., Di Marcotullio L. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. EMBO J. 2015, 34:200-217.
105. Li B., Fei D.L., Flaveny C.A., Dahmane N., Baubet V., Wang Z., Bai F., Pei X.H., Rodriguez-Blanco J., Hang B., Orton D., Han L., Wang B., Capobianco A.J., Lee E., Robbins D.J. Pyrvinium attenuates hedgehog signaling downstream of smoothened. Cancer Res. 2014, 74:4811-4821.
106. Hosoya T., Arai M.A., Koyano T., Kowithayakorn T., Ishibashi M. Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription. Chembiochem 2008, 9:1082-1092.
107. Bosco-Clement G., Zhang F., Chen Z., Zhou H.M., Li H., Mikami I., Hirata T., Yagui-Beltran A., Lui N., Do H.T., Cheng T., Tseng H.H., Choi H., Fang L.T., Kim I.J., Yue D., Wang C., Zheng Q., Fujii N., Mann M., Jablons D.M., He B. Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene 2014, 33:2087-2097.
108. Wolff F., Loipetzberger A., Gruber W., Esterbauer H., Aberger F., Frischauf A.M. Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene 2013, 32:5574-5581.
109. Nebbioso A., Carafa V., Benedetti R., Altucci L. Trials with 'epigenetic' drugs: an update. Mol. Oncol. 2012, 6:657-682.
110. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 2014, 13:673-691.
111. West A.C., Johnstone R.W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 2014, 124:30-39.
112. Coni S., Antonucci L., D'Amico D., Di Magno L., Infante P., De Smaele E., Giannini G., Di Marcotullio L., Screpanti I., Gulino A., Canettieri G. Gli2 acetylation at lysine 757 regulates hedgehog-dependent transcriptional output by preventing its promoter occupancy. PLoS One 2013, 8:e65718.
113. Spiller S.E., Ditzler S.H., Pullar B.J., Olson J.M. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J. Neurooncol. 2008, 87:133-141.
114. Spiller S.E., Ravanpay A.C., Hahn A.W., Olson J.M. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J. Neurooncol. 2006, 79:259-270.
115. Dhanyamraju P.K., Holz P.S., Finkernagel F., Fendrich V., Lauth M. Histone deacetylase 6 represents a novel drug target in the oncogenic hedgehog signaling pathway. Mol. Cancer Ther. 2015, 14:727-739.
116. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., Philpott M., Munro S., McKeown M.R., Wang Y., Christie A.L., West N., Cameron M.J., Schwartz B., Heightman T.D., La Thangue N., French C.A., Wiest O., Kung A.L., Knapp S., Bradner J.E. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
117. Henssen A., Thor T., Odersky A., Heukamp L., El-Hindy N., Beckers A., Speleman F., Althoff K., Schafers S., Schramm A., Sure U., Fleischhack G., Eggert A., Schulte J.H. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 2013, 4:2080-2095.
118. Venkataraman S., Alimova I., Balakrishnan I., Harris P., Birks D.K., Griesinger A., Amani V., Cristiano B., Remke M., Taylor M.D., Handler M., Foreman N.K., Vibhakar R. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget 2014, 5:2355-2371.
119. Tang Y., Gholamin S., Schubert S., Willardson M.I., Lee A., Bandopadhayay P., Bergthold G., Masoud S., Nguyen B., Vue N., Balansay B., Yu F., Oh S., Woo P., Chen S., Ponnuswami A., Monje M., Atwood S.X., Whitson R.J., Mitra S., Cheshier S.H., Qi J., Beroukhim R., Tang J.Y., Wechsler-Reya R., Oro A.E., Link B.A., Bradner J.E., Cho Y.J. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 2014, 20:732-740.
120. Bhatia B., Hsieh M., Kenney A.M., Nahle Z. Mitogenic Sonic hedgehog signaling drives E2F1-dependent lipogenesis in progenitor cells and medulloblastoma. Oncogene 2011, 30:410-422.
121. Kuhajda F.P., Pizer E.S., Li J.N., Mani N.S., Frehywot G.L., Townsend C.A. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3450-3454.
122. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
123. Flavin R., Peluso S., Nguyen P.L., Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010, 6:551-562.
124. Bhatia B., Potts C.R., Guldal C., Choi S., Korshunov A., Pfister S., Kenney A.M., Nahle Z.A. Hedgehog-mediated regulation of PPARgamma controls metabolic patterns in neural precursors and shh-driven medulloblastoma. Acta Neuropathol. 2012, 123:587-600.
125. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., Davis R.G., Hull-Ryde E.A., Lenhard J.M., Patel L., Plunket K.D., Shenk J.L., Stimmel J.B., Therapontos C., Willson T.M., Blanchard S.G. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002, 41:6640-6650.
126. Seargent J.M., Yates E.A., Gill J.H. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br. J. Pharmacol. 2004, 143:933-937.
127. Gershon T.R., Crowther A.J., Tikunov A., Garcia I., Annis R., Yuan H., Miller C.R., Macdonald J., Olson J., Deshmukh M. Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer Metab. 2013, 1:2.
128. Rathmell J.C., Fox C.J., Plas D.R., Hammerman P.S., Cinalli R.M., Thompson C.B. Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 2003, 23:7315-7328.
129. Gottlob K., Majewski N., Kennedy S., Kandel E., Robey R.B., Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001, 15:1406-1418.
130. Vaughn A.E., Deshmukh M. Glucose metabolism inhibits apoptosis in neurons and cancer cells by redox inactivation of cytochrome c. Nat. Cell Biol. 2008, 10:1477-1483.
131. Di Magno L., Manzi D., D'Amico D., Coni S., Macone A., Infante P., Di Marcotullio L., De Smaele E., Ferretti E., Screpanti I., Agostinelli E., Gulino A., Canettieri G. Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth. Cell Cycle 2014, 13:3404-3413.
132. Pereira da Silva A.P., El-Bacha T., Kyaw N., dos Santos R.S., da-Silva W.S., Almeida F.C., Da Poian A.T., Galina A. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem. J. 2009, 417:717-726.
133. Kankotia S., Stacpoole P.W. Dichloroacetate and cancer: new home for an orphan drug?. Biochim. Biophys. Acta 2014, 1846:617-629.
134. Stacpoole P.W., Henderson G.N., Yan Z., Cornett R., James M.O. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab. Rev. 1998, 30:499-539.
135. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Bonnet S., Harry G., Hashimoto K., Porter C.J., Andrade M.A., Thebaud B., Michelakis E.D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
136. Sun R.C., Fadia M., Dahlstrom J.E., Parish C.R., Board P.G., Blackburn A.C. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res. Treat. 2010, 120:253-260.
137. Sutendra G., Dromparis P., Kinnaird A., Stenson T.H., Haromy A., Parker J.M., McMurtry M.S., Michelakis E.D. Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer. Oncogene 2013, 32:1638-1650.